• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD

PRODUCT FILTERS

REGION

30
2
2
2
1

COUNTRY

2

PRICE

4
7
9
37

PUBLISHED

0
0
2
37

PRODUCT TYPE

34
3

Lymphoma

Lymphoma encompasses a variety of blood cancers of the lymphatic system. Non-Hodgkin’s Lymphoma (NHL) for example, is diagnosed in over 100,000 every year in the US and EU combined. An array of expert reports in our Lymphoma Section enable you to investigate drug development strategies and market trends for NHL, Hodgkin’s Lymphoma, Skin Lymphoma, T-Cell Lymphoma, Indolent Lymphoma and other variants. Investigate key issues such as licensing, R&D, industry alliances, generic drugs (rituximab, bortezomib, doxorubicin, bleomycin, vinblastine, etc.) and the activities of major pharmaceutical players such as Bristol-Myers Squibb, GlaxoSmithKline, Hoffmann-La Roche, and Sanofi-Aventis. Show Less Read more

PRODUCT TITLE
Triple Analysis: Lung Cancer, Lymphoma and Angiogenesis Triple Analysis: Lung Cancer, Lymphoma and Angiogenesis - Product Thumbnail Image

Triple Analysis: Lung Cancer, Lymphoma and Angiogenesis

This triple analysis focuses on cancer drug development strategies in both Lung Cancer and Lymphoma and by the mechanism/target/effect of Angiogenesis. Each of these three individual parts is evaluated...

January 2012
Triple Analysis: Leukemia, Lymphoma and Apoptosis Triple Analysis: Leukemia, Lymphoma and Apoptosis - Product Thumbnail Image

Triple Analysis: Leukemia, Lymphoma and Apoptosis

This triple analysis focuses on cancer drug development strategies in both Leukemia and Lymphoma and by the mechanism/target/effect of Apoptosis. Each of these three individual parts is evaluated according...

December 2011
FROM
Triple Analysis: Colorectal Cancer, Lymphoma and Apoptosis Triple Analysis: Colorectal Cancer, Lymphoma and Apoptosis - Product Thumbnail Image

Triple Analysis: Colorectal Cancer, Lymphoma and Apoptosis

This triple analysis focuses on cancer drug development strategies in both Colorectal Cancer and Lymphoma and by the mechanism/target/effect of Apoptosis. Each of these three individual parts is evaluated...

December 2011
FROM
Triple Analysis: Colorectal Cancer, Lung Cancer and Lymphoma Triple Analysis: Colorectal Cancer, Lung Cancer and Lymphoma - Product Thumbnail Image

Triple Analysis: Colorectal Cancer, Lung Cancer and Lymphoma

This triple analysis focuses on cancer drug development strategies in Colorectal Cancer, Lung Cancer and Lymphoma. Each of these three individual parts is evaluated according to standardized criteria...

July 2011
FROM
Triple Analysis: Leukemia, Lung Cancer and Lymphoma Triple Analysis: Leukemia, Lung Cancer and Lymphoma - Product Thumbnail Image

Triple Analysis: Leukemia, Lung Cancer and Lymphoma

This triple analysis focuses on cancer drug development strategies in Leukemia, Lung Cancer and Lymphoma. Each of these three individual parts is evaluated according to standardized criteria in a five...

July 2011
FROM
Brentuximab Vedotin - First Treatment Option for Relapsed Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma (Subset of Non-Hodgkin Lymphoma) Brentuximab Vedotin - First Treatment Option for Relapsed Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma (Subset of Non-Hodgkin Lymphoma) - Product Thumbnail Image

Brentuximab Vedotin - First Treatment Option for Relapsed Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma (Subset of Non-Hodgkin Lymphoma)

Brentuximab Vedotin – First Treatment Option for Relapsed Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma (Subset of Non-Hodgkin Lymphoma) Summary The group of cancers that originate in the lymphatic...

May 2011
FROM
A Decision Support Tool for Optimizing The Lymphoma Pipeline: From Research and Development to Market A Decision Support Tool for Optimizing The Lymphoma Pipeline: From Research and Development to Market - Product Thumbnail Image

A Decision Support Tool for Optimizing The Lymphoma Pipeline: From Research and Development to Market

This report comprises defined and up to date development strategies for 282 lymphoma drugs within the portfolio of 152 companies, from Ceased to Marketed The report extensively analyses their 181 identified...

May 2011
FROM
2011 Global Markets for External Radiation Therapy 2011 Global Markets for External Radiation Therapy - Product Thumbnail Image

2011 Global Markets for External Radiation Therapy

2011 Global Markets for External Radiation Therapy is a comprehensive market intelligence solution designed for senior executives who are looking for: - High quality, granular, deeply segmented data...

May 2011
FROM
2011 O.U.S. Markets For External Radiation Therapy 2011 O.U.S. Markets For External Radiation Therapy - Product Thumbnail Image

2011 O.U.S. Markets For External Radiation Therapy

2011 O U S Markets For External Radiation Therapy is a comprehensive market intelligence solution designed for senior executives who are looking for: - High quality, granular, deeply segmented data...

May 2011
FROM
2011 U.S. Markets for External Radiation Therapy 2011 U.S. Markets for External Radiation Therapy - Product Thumbnail Image

2011 U.S. Markets for External Radiation Therapy

2011 U S Markets for External Radiation Therapy is a comprehensive market intelligence solution designed for senior executives who are looking for: - High quality, granular, deeply segmented data -...

May 2011
FROM

Angioimmunoblastic T-cell Lymphoma (AILT)/Immunoblastic Lymphadenopathy Global Clinical Trials Review, Q1, 2011

Angioimmunoblastic T-cell Lymphoma (AILT)/Immunoblastic Lymphadenopathy Global Clinical Trials Review, Q1, 2011 Summary A clinical trial report, “Angioimmunoblastic T-Cell Lymphoma (AILT)/Immunoblastic...

January 2011
FROM

Indolent Lymphoma Global Clinical Trials Review, Q1, 2011

Indolent Lymphoma Global Clinical Trials Review, Q1, 2011 Summary Our clinical trial report, “Indolent Lymphoma Global Clinical Trials Review, Q1, 2011" provides data on the Indolent Lymphoma clinical...

January 2011
FROM

Lymphoma Global Clinical Trials Review, Q1, 2011

Lymphoma Global Clinical Trials Review, Q1, 2011 Summary Our clinical trial report, “Lymphoma Global Clinical Trials Review, Q1, 2011" provides data on the Lymphoma clinical trial scenario. This report...

January 2011
FROM
Lymphoma Therapeutics - Global Strategic Business Report Lymphoma Therapeutics - Global Strategic Business Report - Product Thumbnail Image

Lymphoma Therapeutics - Global Strategic Business Report

This report analyzes the worldwide markets for Lymphoma Therapeutics in US$ Million The report provides separate comprehensive analytics for US, Europe, and Rest of World Annual estimates and forecasts...

April 2010
FROM
European Non-Hodgkin's Lymphoma Therapeutics Markets European Non-Hodgkin's Lymphoma Therapeutics Markets - Product Thumbnail Image

European Non-Hodgkin's Lymphoma Therapeutics Markets

This Frost & Sullivan research service titled European Non-Hodgkin’s Lymphoma Therapeutics Markets provides drivers, restraints and revenue forecasts for this market In this research, Frost & Sullivan's...

December 2007
FROM

Lymphoid Malignancies: An Atlas of Investigation and Diagnosis

Meeting the needs for haematologists and clinical chemists for an up to date reference, this atlas provides a visual presentation of lymphoproliferative disorders, leukaemia and plasma cell neoplasms...

September 2007
FROM

Therapeutic Strategies in Lymphoid Malignancies: An Immunotherapeutic Approach

Targeted therapies are the focus of much research in oncology Encouraging results from the development of new monoclonal antibodies are revolutionizing clinical therapies and this is particularly the...

August 2005
FROM
Loading Indicator

Our Clients

Takeda Pharmaceutical Company Limited GlaxoSmithKline PLC Accuray Incorporated Becton, Dickinson and Company (BD) Novartis AG Elekta AB